



# Maple-Brown Abbott Asian Investment Trust

Monthly Factsheet – 31 March 2024

## Fund facts

Fund size	\$38 million
Inception date	25 Oct 2002
APIR code	MPL0003AU
Distribution frequency	Quarterly
Management fees and costs <sup>1</sup>	1.09% p.a.
Minimum investment <sup>1</sup>	\$20,000
Minimum withdrawal <sup>1</sup>	\$1,000
Buy/sell spread <sup>1</sup>	0.24%/0.24%
Application price (AUD)	\$1.0281
Redemption price (AUD)	\$1.0231

## Fund snapshot

### Objective

The Fund aims to outperform the MSCI All Countries Asia Excluding Japan Net Index (AUD) (Benchmark), after fees, over a four-year period.

### Asset allocation ranges

Asia (ex-Japan) equities	90-100%
Cash	0-10%

### Investment philosophy

Value, active, bottom up

### Portfolio manager

William Main


## Overview

The Maple-Brown Abbott Asian Investment Trust (the “Fund”) is invested in companies listed (or expected to be listed) across Asia (ex-Japan) and is actively managed. We may also invest in companies listed outside Asia that conduct the majority of their operations in Asia. Our value-based investment philosophy underlies our approach to stock selection, driven by our bottom-up research process designed to maximise the opportunities to deliver income and long-term capital growth to our clients. We use several valuation screens to rank our investment universe and generate stock ideas. Our experienced team then undertakes detailed quantitative and qualitative analysis to identify companies that are trading at a discount to our assessment of their underlying value. The Fund provides exposure to a diversified portfolio of our highest conviction opportunities which we expect to deliver strong risk-adjusted returns over the long-term. We aim to invest across a broad universe of Asia (ex-Japan) companies and will typically hold 40–60 stocks.

## Performance (%) <sup>2</sup>

	Fund <sup>3</sup>	Benchmark <sup>4</sup>
1 month	2.6	2.3
3 months	6.8	7.1
1 year	5.0	6.8
3 years p.a.	2.0	-1.9
4 years p.a.	8.7	4.5
5 years p.a.	4.3	3.7
Since inception p.a.	9.1	7.9

## Value of \$100 invested at inception



## Top 5 holdings (%)

	Weighting
Taiwan Semiconductor Manufact. Co	11.6
Samsung Electronics	8.4
Tencent Holdings	7.4
HDFC Bank Ltd	4.3
Alibaba Group Holding (HK)	3.9

### Notes:

- Additional fees and costs may also apply in relation to an investment in the Fund. For a full description of the fees and costs refer to the Fund Product Disclosure Statement (“PDS”) and Additional Information Booklet (“AIB”) for the Fund.
- Past performance is not a reliable indicator of future performance. Source: Maple-Brown Abbott Ltd, MSCI as at 31 March 2024.
- The Fund’s performance is based on the movement in net asset value per unit plus distributions and is before tax and after all fees and charges. Imputation and foreign tax credits are not included in the performance figures.
- Benchmark: MSCI AC Asia ex-Japan Net Index AUD.

## Want to find out more?

Contact our Client Service team by:

T 1300 097 995

E [mba@unitregistry.com.au](mailto:mba@unitregistry.com.au)

W [maple-brownabbott.com](http://maple-brownabbott.com)

# Maple-Brown Abbott Asian Investment Trust

Monthly Factsheet – 31 March 2024

## Portfolio characteristics <sup>5</sup>

	Fund	Market overall <sup>6</sup>
Price: Earnings ratio	11.1	13.5
Price: Cash flow ratio	6.8	9.1
Price: Net tangible assets ratio	1.3	1.6
Dividend yield %	3.1	2.7
Balance sheet strength <sup>7</sup>	0.40	0.38


## Risk measures

	Fund	Benchmark
Monthly volatility % p.a. <sup>8</sup>	14.1	13.8
Tracking error (ex-ante) <sup>9</sup>	3.9	
Beta vs Benchmark <sup>9</sup>	1.0	


## Annual distributions

Year	Cents per unit	Distribution return %
30 June 2023	1.9803	2.3
30 June 2022	10.1001	8.7
30 June 2021	8.9810	10.4
30 June 2020	9.9502	8.0
30 June 2019	14.9117	12.3

## Fund sector weight (%)



## Fund country weight (%)



For latest Fund commentary [click here](#).

### Notes:

- The portfolio characteristics are based on the underlying securities held within the Fund/Market overall. The figures shown for the Fund are our own estimates for the next 12 months having regard to available information on the underlying companies as at 31 March 2024 and are subject to change without notice. The Market overall is an estimate for the next 12 months based on estimates from UBS, Macquarie and Maple-Brown Abbott. These figures are based on certain assumptions (including forecasting a company's earnings, profit, cash flows, balance sheet, estimating payout ratio and Franking levels) which may be inaccurate or impacted by unknown risks. Actual outcomes may vary in a materially positive or negative manner.
- The Market overall data represents our quantitative data which includes 88.3% of the index weight of the stocks in the Benchmark, plus non-Benchmark stocks.
- Balance sheet strength is calculated as Cash flow/Total liabilities. Refer footnote 5 for further detail.
- Volatility is at since inception 25 October 2002. The volatility is calculated for both the Fund and Benchmark. Volatility calculation is annualised and is the standard deviation of monthly returns.
- Source: UBS as at 31 March 2024.

### Disclaimer

This document is prepared and issued by Maple-Brown Abbott Limited ABN 73 001 208 564, AFSL 237296 ("MBA"). It does not constitute advice of any kind and should not be relied upon as such. This document must not be reproduced or transmitted in any form without the prior written consent of MBA. This document does not constitute investment advice or an investment recommendation of any kind and should not be relied upon as such. This document contains general information only, and does not take into account your investment objectives, financial situation or specific needs. Before making any investment decision, you should seek independent investment, legal, tax, accounting or other professional advice as appropriate. This document does not constitute an offer or solicitation by anyone in any jurisdiction. This document is not an advertisement and is not directed at any person in any jurisdiction where the publication or availability of the information is prohibited or restricted by law. Past performance is not a reliable indicator of future performance. Neither MBA, nor any of its related parties, directors or employees, make any representation or give any guarantee as to the return of capital, performance, any specific rate of return, or the taxation consequences of, any investment. Any comments about investments are not a recommendation to buy, sell or hold. Any views expressed on individual stocks or other investments, or any forecasts or estimates, are not a recommendation to buy, sell or hold, they are point in time views and may be based on certain assumptions and qualifications not set out in part or in full in this document. The views and opinions contained in this document are those of the authors as at the date of publication and are subject to change due to market and other conditions. Such views and opinions may not necessarily represent those expressed or reflected in other MBA communications, strategies or funds. Information derived from sources is believed to be accurate, however such information has not been independently verified and may be subject to assumptions and qualifications compiled by the relevant source and this document does not purport to provide a complete description of all or any such assumptions and qualifications. To the extent permitted by law, neither MBA, nor any of its related parties, directors or employees, make any representation or warranty as to the accuracy, completeness, reasonableness or reliability of this information, or accept liability or responsibility for any losses, whether direct, indirect or consequential, relating to, or arising from, the use or reliance on this information. Units in the Trust are issued by MBA. Before making a decision whether to acquire, or to continue to hold an investment in the Trust, you should obtain and consider the current Product Disclosure Statement, Additional Information Booklet and Target Market Determination for the Trust issued by MBA and available at [maple-brownabbott.com/document-library/](http://maple-brownabbott.com/document-library/) or by calling 1300 097 995. An investment in the Trust does not represent an investment in, deposit with or other liability of MBA, and is subject to investment risk including possible delays in repayment and loss of income and principal invested. This information is current as at 31 March 2024 and is subject to change at any time without notice.

MSCI: The MSCI information may only be used for your internal use, may not be reproduced or disseminated in any form and may not be used as a basis for or a component of any financial instruments or products or indices. None of the MSCI information is intended to constitute investment advice or a recommendation to make (or refrain from making) any kind of investment decision and may not be relied on as such. Historical data and analysis should not be taken as an indication or guarantee of any future performance analysis, forecast or prediction. The MSCI information is provided on an "as is" basis and the user of this information assumes the entire risk of any use made of this information. MSCI, each of its affiliates and each other person involved in or related to compiling, computing or creating any MSCI information (collectively, the "MSCI Parties") expressly disclaims all warranties (including, without limitation, any warranties of originality, accuracy, completeness, timeliness, non-infringement, merchantability and fitness for a particular purpose) with respect to this information. Without limiting any of the foregoing, in no event shall any MSCI Party have any liability for any direct, indirect, special, incidental, punitive, consequential (including, without limitation, lost profits) or any other damages. [www.msci.com].



Signatory of:



## Want to find out more?

Contact our Client Service team by:

T 1300 097 995

E [mba@unitregistry.com.au](mailto:mba@unitregistry.com.au)

W [maple-brownabbott.com](http://maple-brownabbott.com)